


Interest of *in vivo* CEST MRI to study chondrosarcoma tumour microenvironment

R. Autissier^{1,2}, E. Maubert¹, S. Schmitt¹, P. Auzeloux¹, C. Peyrode¹, F. Degoul¹, A. Traoré², J. M. Bonny², E. Miot-Noirault¹, L. Mazuel^{1,2} & G. Pagès²

¹ Université Clermont Auvergne, INSERM, UMR1240 IMoST, 63000 Clermont-Ferrand, France

² INRA, AgroResonance, UR370 QuaPA, 63122 Saint-Genès-Champanelle, France

Contact: Roxane.Autissier@uca.fr



Introduction:

Chondrosarcoma is a malignant cartilage tumour and represents the second most common primary malignant solid tumour of bone. It accounts for approximately 25% of all bone sarcomas (Bertoni *et al.* 2002). Poorly vascularized and rich in proteoglycans (PGs), chondrosarcomas are considered to be chemo- and radio-resistant with efficient treatment usually limited to surgical resection with large disease-free margins. If the hypoxic and PGs status of the tumour can be assessed by TEP imaging and scintigraphy, it requires however 2 separated exams.


In this context, we propose to develop an MRI strategy based on Chemical Exchange Saturation Transfer (CEST) to simultaneously co-register both hypoxia (pH) and PGs content *in vivo*.

Materials and Methods:

In vivo model of chondrosarcoma: 5 week female nude NMRI mice (n=10) were implanted with rat chondrosarcoma SWARM xenograft (1mm³ fragment) in scapula position. After 2 weeks growth (average tumour volume: 215,04 mm³ ± 86,27), xenografts were characterized in terms of PGs content by ²³Na MRI, ^{99m}Tc-NTP 15-5 radiotracer (developed in UMR 1240 INSERM, Peyrode *et al.* 2011) and hypoxia by ¹⁸F-FMISO (Rajendran *et al.* 2015). Then, both tumour characteristics were evaluated by CEST MRI.


In vivo multimodal imaging: All acquisitions were performed on anesthetized mice (1.5% isoflurane in air/O₂ 70/30, v/v, mixture). **MRI acquisitions:** MRI images were acquired at 11.7 T using a 72-mm volume quadratic coil with surface reception. Diffusion weighted imaging (b=500s.mm⁻²) was first performed to localize the tumour, then WASSR (B₁=0,1μT for 1s, Δωsat=±1000Hz in 20Hz steps) and CEST Z-spectra (B₁=1.5μT for 4s, Δωsat=±2500Hz in 50Hz steps) were acquired based on a RARE sequence. ²³Na MRI was recorded thanks to a FLASH sequence in axial plane. Data were analysed using an in-house program written on MathWorks®. After correction for B₀ inhomogeneities, the CEST maps were generated and Area Under the Curve (AUC) were calculated at given frequencies on Z-spectra asymmetries with MTRAsym or three-offset measurement approaches (Jin *et al.* 2013). **Scintigraphic imaging:** ^{99m}Tc-NTP15-5 (13MBq/animal) and ¹⁸F-FMISO (18MBq/animal) were administered intravenously then acquisitions were performed 30min or 4h after injection with 15min planar acquisition, respectively. Data were analysed using Interview™FUSION and VivoQuant™.

Ex vivo analysis: the presence of PGs and hypoxia was assessed by Alcian blue and pimonidazole staining respectively.



Results:


1/Evaluation of proteoglycans content



High accumulation of ^{99m}Tc-NTP15-5 inside the tumour reflects the presence of PGs content

High alcian blue staining illustrates the high PGs content

2/Evaluation of hypoxia (pH)




¹⁸F-FMISO uptake inside chondrosarcoma reflects mild hypoxia

Pimonidazole staining confirms the presence of tumour hypoxic areas


CEST MRI

²³Na MRI imaging:




²³Na MRI reflects the presence of PGs

CEST MRI - hydroxyls functions for PGs imaging:



AUC of hydroxyls functions can confirm large presence of PGs inside the tumour

CEST MRI - amines and amides functions for pH imaging:



Cartography of AUC between 1000-1200Hz (amine moiety) suggests regional changes in pH within chondrosarcoma

Conclusion – Discussion:

Preliminary findings reveal potential of CEST MRI as multimodal imaging approach. In a unique acquisition, CEST MRI provides *in vivo* quantitative data of extracellular matrix as well as a high resolution cartography of hypoxia.

Perspectives are now to evaluate CEST MRI as an *in vivo* method to assess response to therapy.

Grants: “La Ligue contre le Cancer Auvergne-Rhône-Alpes”. MRI and nuclear imaging were performed at AgroResonance and UMR 1240 INSERM respectively, in the context of IBISA labelled IVIA platform.